VFA
MRTX

Virtus Fund Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Virtus Fund Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$361K Buy
+19,786
New +$307K ﹤0.01% 387
2014
Q3 		– Sell
-612
Closed -$12K – 2047
2014
Q2 		$12K Buy
+612
New +$11.8K ﹤0.01% 2717

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Virtus Fund Advisers's MRTX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2017: 19,786 shares worth $361K. The stake represents ﹤0.01% of the portfolio and ranks #387 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in MRTX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in MRTX in Q2 2014 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold MRTX as of Q4 2017.

  • Virtus Fund Advisers held 19,786 shares of Mirati Therapeutics, Inc. Common Stock worth $361K as of Q4 2017.
  • Mirati Therapeutics, Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #387 holding.
  • Virtus Fund Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.